Edward Hodgkin is a Partner of Syncona Partners LLP and a Non-Executive Director of Autolus Ltd, where he served as CEO from the company’s inception in September 2014 until March 2016. Autolus is developing a series of next-generation engineered T-cell products for treatment of haematological and solid tumours, based on its proprietary targets, constructs and technologies. Previously, he was CEO of Biotica Technology Ltd (Cambridge, UK) from 2007 to 2012. Prior to joining Biotica, Ed spent 12 years in the US, serving as President & Chief Business Officer of BrainCells Inc (San Diego, CA) and VP, Business Development & Marketing at Tripos Inc (St Louis, MO). His early career was spent in scientific and management roles at Wyeth-Ayerst Inc (Princeton, NJ) and British Biotech Ltd (Oxford, UK). Ed holds an MA and DPhil in Chemistry from Oxford University and is a Non-Executive Director and former Chairman of the BioIndustry Association (BIA), the UK’s trade association representing innovative life science companies.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.